糖原
内分泌学
内科学
生物
下调和上调
信号转导
甲状腺激素受体
转录组
糖原合酶
甲状腺
甲状腺激素受体β
癌细胞
受体
细胞
激素
甲状腺癌
细胞信号
碳水化合物代谢
甲状腺间变性癌
细胞生长
细胞内
肿瘤微环境
基因表达
激素受体
癌症研究
GSK3B公司
细胞生物学
化学
基因表达调控
癌症
甲状腺激素受体α
作者
Justin M Zielinski,Jennifer A. Tomczak,Eyal Amiel,Frances E. Carr
出处
期刊:Endocrinology
[Oxford University Press]
日期:2025-10-22
卷期号:166 (12)
标识
DOI:10.1210/endocr/bqaf156
摘要
Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine cancers with no enduring therapies. Thyroid hormone receptor β (TRβ), a recognized tumor suppressor, modulates the transcriptome altering gene expression in numerous intracellular signaling pathways. Our recent studies revealed that TRβ agonism inhibits glycogen metabolism in ATC cells. Our goal in the present study was to delineate the molecular mechanisms by which TRβ regulates glycogen synthesis and breakdown. In ATC cells, activation of TRβ induced changes in expression of genes and proteins in glycogen signaling concordant with downregulation of cancer metabolism. The impact on the cancer cell metabolic phenotype was determined by glycogen levels, cell viability, and reactive oxygen species characterization. Our results revealed that TRβ activation differentially regulates glycogen signaling pathways reflective of the genetic landscape of the cells. This suggests TRβ can suppress tumor growth and progression through multiple steps in glycogen metabolism, giving it a unique and distinct role in fine-tuning the microenvironment of the cell as an internal sensor of the general environment of the cell. These studies reveal the potential of a synergistic effect of TRβ agonism and inhibition of glycogen metabolism in the treatment of aggressive dedifferentiated thyroid cancers.
科研通智能强力驱动
Strongly Powered by AbleSci AI